Superior clinical impact of FDG-PET compared to MRI for the follow-up of a patient with sacral lymphoma.
(75/166)
The assessment of residual tumors after treatment of malignant lymphoma (ML) is often difficult. Here we report a case of non-Hodgkin's lymphoma with a huge sacral tumor. After chemotherapy and following radiation therapy, a residual mass was detected on magnetic resonance imaging (MRI). However, a hypermetabolic lesion in the sacrum disappeared on (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and clinically the patient was considered to achieve complete remission. Seven months after the completion of radiation therapy, a new tumor-like lesion in the sacrum developed on MRI, but hypermetabolic lesions were not detected on (18)F-FDG-PET. Recurrence of lymphoma was denied by open biopsy of the lesion. (18)F-FDG-PET has been of widespread use not only for staging but for post-treatment assessment of ML. Although MRI is a standard imaging tool for the assessment of bone involvement of ML, there have been few reports documenting the results of comparative studies on the usefulness of (18)F-FDG-PET and MRI for the evaluation of residual mass in bone involvement of ML. The present case suggests that (18)F-FDG-PET is superior to MRI not only in the evaluation of a residual mass but in the judgment of recurrence after treatment of such patients. (+info)
Sacral nerve stimulation as a treatment modality for intractable neuropathic testicular pain.
(76/166)
BACKGROUND: Chronic testicular pain, or "chronic orchalgia," is defined as testicular pain 3 months or longer in duration that significantly interferes with the daily activities of the patient. For patients failing to respond to conservative treatment, microsurgical denervation of the spermatic cord, epididymectomy, and vasovasostomy have all shown a degree of relief. However, these are all invasive procedures and no treatment has proven efficacy when these options fail. We present a case of a male who presented with over a decade of chronic right-sided testicular pain secondary to recurrent epididymitis. Before arriving at our clinic the patient had an epididymectomy performed with no appreciable improvement in pain. Initially ilioinguinal, iliohypogastric, and genetofemoral nerve blocks; right-sided S1, S2, and S3 transforaminal epidural steroid injections (TFESIs) with inferior hypogastric blocks; and right-sided T12-L1, L1-L2, and L2-L3 TFESIs all failed to provide pain relief. After conservative therapies had failed, a sacral nerve stimulation trial was done via a caudal epidural approach. The permanent implant has provided the patient with sustained 80% decrease in pain at 4 months status post permanent sacral nerve stimulation implant. The above case demonstrates the potential benefit of sacral nerve stimulation with neuropathic intractable testicular pain in a patient that failed conservative treatment. In this case, the patient had exhausted medical and surgical management, including advanced interventional pain options. We were unable to find any previous published cases of neurostimulation used as a modality of treatment for testicular pain, and further studies are needed to gain a better understanding of the efficacy in this setting. (+info)
Reduction of lumbar scoliosis by use of a heel lift to level the sacral base.
(77/166)
The relationship between unlevelness of the sacral base and scoliosis is unclear. A method for reducing mild lateral bend of the lumbar spine by use of a heel lift to level the sacral base was tested in adults. Special methods were used to demonstrate the weight-bearing plane of the sacral base and the angle of lateral bend radiographically. The procedure significantly decreased the unlevelness of the sacral base and significantly reduced the angle of lateral bend. The results suggest that an unlevel sacral base contributes to lumbar scoliosis and that use of a heel lift to level the sacral base in mild cases of lumbar scoliosis can be beneficial. (+info)
Sacrococcygeal pilonidal disease: analysis of previously proposed risk factors.
(78/166)